loading...| Preferred Name |
Lenalidomide |
|
| Synonyms |
lenalidomide Lenalidomide LENALIDOMIDE 3-(4-Amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione CC-5013 CC5013 CDC 501 Revlimid |
|
| Definitions |
A thalidomide analog with potential antineoplastic activity. Lenalidomide inhibits TNF-alpha production, stimulates T cells, reduces serum levels of the cytokines vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), and inhibits angiogenesis. This agent also promotes G1 cell cycle arrest and apoptosis of malignant cells. |
|
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C2668 |
|
| Accepted_Therapeutic_Use_For |
Transfusion-dependent anemia due to low- or intermediate-1 risk myelodysplastic syndrome; multiple myeloma, lymphoma |
|
| ALT_DEFINITION |
A drug that is similar to thalidomide, and is used to treat multiple myeloma and certain types of anemia. It is also being studied in the treatment of other types of cancer. Lenalidomide belongs to the family of drugs called angiogenesis inhibitors. |
|
| CAS_Registry |
191732-72-6 |
|
| CHEBI_ID |
CHEBI:63791 |
|
| Chemical_Formula |
C13H13N3O3 |
|
| code |
C2668 |
|
| Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C176424 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157711 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C173381 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157712 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C173383 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116978 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C201600 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128784 |
|
| Contributing_Source |
CTRP FDA GDC HemOnc |
|
| DEFINITION |
A thalidomide analog with potential antineoplastic activity. Lenalidomide inhibits TNF-alpha production, stimulates T cells, reduces serum levels of the cytokines vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), and inhibits angiogenesis. This agent also promotes G1 cell cycle arrest and apoptosis of malignant cells. |
|
| Display_Name |
Lenalidomide |
|
| FDA_UNII_Code |
F0P408N6V4 |
|
| FULL_SYN |
lenalidomide Lenalidomide LENALIDOMIDE 3-(4-Amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione CC-5013 CC5013 CDC 501 Revlimid |
|
| Has_Target |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C20547 |
|
| Is_Value_For_GDC_Property | ||
| label |
Lenalidomide |
|
| Legacy Concept Name |
CC-5013 |
|
| Maps_To |
Lenalidomide |
|
| NCI_Drug_Dictionary_ID |
38564 |
|
| NSC Number |
703813 |
|
| PDQ_Closed_Trial_Search_ID |
38564 |
|
| PDQ_Open_Trial_Search_ID |
38564 |
|
| Preferred_Name |
Lenalidomide |
|
| prefixIRI |
Thesaurus:C2668 |
|
| PubMedID_Primary_Reference |
16085014 |
|
| Semantic_Type |
Organic Chemical Pharmacologic Substance |
|
| UMLS_CUI |
C1144149 |
|
| subClassOf |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1742 |